Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Akero Therapeutics Inc (NASDAQ: AKRO) was $38.64 for the day, down -4.55% from the previous closing price of $40.48. In other words, the price has decreased by -$4.55 from its previous closing price. On the day, 1.79 million shares were traded. AKRO stock price reached its highest trading level at $41.71 during the session, while it also had its lowest trading level at $38.49.
Ratios:
Our analysis of AKRO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 19.38 and its Current Ratio is at 19.38. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on January 30, 2025, Upgraded its rating to Buy and sets its target price to $63 from $35 previously.
On January 27, 2025, H.C. Wainwright reiterated its Buy rating and also lowered its target price recommendation from $50 to $72.
On November 18, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $65.Citigroup initiated its Buy rating on November 18, 2024, with a $65 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 25 ’25 when Graham G. Walmsley bought 91,309 shares for $44.75 per share. The transaction valued at 4,085,804 led to the insider holds 1,091,309 shares of the business.
Graham G. Walmsley bought 58,691 shares of AKRO for $2,524,417 on Mar 26 ’25. The Director now owns 1,150,000 shares after completing the transaction at $43.01 per share. On Mar 27 ’25, another insider, Graham G. Walmsley, who serves as the Director of the company, bought 50,000 shares for $43.55 each. As a result, the insider paid 2,177,700 and bolstered with 1,200,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKRO now has a Market Capitalization of 3076520448 and an Enterprise Value of 2369560832.
Stock Price History:
The Beta on a monthly basis for AKRO is -0.18, which has changed by 0.6669543 over the last 52 weeks, in comparison to a change of 0.08089435 over the same period for the S&P500. Over the past 52 weeks, AKRO has reached a high of $58.40, while it has fallen to a 52-week low of $17.86. The 50-Day Moving Average of the stock is -16.16%, while the 200-Day Moving Average is calculated to be 19.92%.
Shares Statistics:
AKRO traded an average of 1.36M shares per day over the past three months and 1074470 shares per day over the past ten days. A total of 72.38M shares are outstanding, with a floating share count of 70.68M. Insiders hold about 11.23% of the company’s shares, while institutions hold 86.44% stake in the company. Shares short for AKRO as of 1741910400 were 5203442 with a Short Ratio of 3.83, compared to 1739491200 on 4785670. Therefore, it implies a Short% of Shares Outstanding of 5203442 and a Short% of Float of 6.7.
